GEN Exclusives

More »

GEN News Highlights

More »
Aug 25, 2009

TTY Biopharm to Produce to-BBB’s Brain Cancer Candidate

  • Dutch biotech company to-BBB is enlisting the help of Taiwanese drug formulation firm TTY Biopharm for the future manufacture of clinical-grade brain-targeting doxorubicin liposome candidate for the treatment of brain cancer

    TTY operates an EMEA-approved facility in ChangLi and already manufactures and markets Lipo-Dox®, a pegylated liposomal doxorubicin, in the Taiwanese and Asian markets. The company’s core technologies include liposomal, microemulsion, and sustained-release oral and injectable formulations.

    To-BBB’s brain-targeting doxorubicin liposome candidate is currently in preclinical development. The lead product is based on the company’s G-Technology, which involves coating the liposomes with glutathione at the tips of the polyethylene glycol. to-BBB claims the technology improves the safe delivery of free drug to the brain. The G-Technology was originally developed at the Industrial Technology Research Institute in Taiwan. 

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?